Literature DB >> 990283

Affinity chromatography of human plasma and platelet factor XIII on organomercurial agarose.

J Mcdonagh, W G Waggoner, E G Hamilton, B Hindenbach, R P Mcdonagh.   

Abstract

A method for affinity chromatography of plasma and platelet factor XIII has been developed, based on known structural characteristics of these molecules. Plasma factor XIII is composed of a and b subunits which are held together by noncovalent interactions; platelet factor XIII has only a subunits. a subunit contains free sulfhydryl groups, while in b subunit all the cystines form disulfide bonds. The affinity gel is an organomercurial agarose with p-chloromercuribenzoate as the reactive group. Both the zymogen and activated forms of a subunit reversibly bind to the ligand by forming covalent mercaptide bonds and are eluted by reducing agents. b subunit does not bind to the affinity gel and is held to it only through interaction with a subunit. Affinity chromatography can be used to purify plasma and platelet factor XIII and to study interactions of the subunits. Experiments on the affinity chromatography of purified plasma factor XIII in several stages of activation agree with earlier observations that activation is a two-step procedure in which b subunit is not quantitatively released from the complex until the final stage of activation by Ca2+.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 990283     DOI: 10.1016/0005-2795(76)90002-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Identification of intracellular factor XIII in human monocytes and macrophages.

Authors:  P Henriksson; S Becker; G Lynch; J McDonagh
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

2.  A compilation of amino acid analyses of proteins. XVIII. Residues per thousand residues--5.

Authors:  D M Kirschenbaum
Journal:  Appl Biochem Biotechnol       Date:  1983-08       Impact factor: 2.926

3.  Difference between type I autoimmune inhibitors of fibrin stabilization in two patients with severe hemorrhagic disorder.

Authors:  S Lopaciuk; K Bykowska; J M McDonagh; R P McDonagh; W J Yount; C R Fuller; L Cooperstein; A Gray; L Lorand
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

4.  A factor X-activating cysteine protease from malignant tissue.

Authors:  S G Gordon; B A Cross
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

5.  Non-proteolytic activation of cellular protransglutaminase (placenta macrophage factor XIII).

Authors:  J Polgár; V Hidasi; L Muszbek
Journal:  Biochem J       Date:  1990-04-15       Impact factor: 3.857

6.  Secondary-site binding of Glu-plasmin, Lys-plasmin and miniplasmin to fibrin.

Authors:  E Suenson; S Thorsen
Journal:  Biochem J       Date:  1981-09-01       Impact factor: 3.857

7.  Site specific identification of endogenous S-nitrosocysteine proteomes.

Authors:  Paschalis-Thomas Doulias; Margarita Tenopoulou; Karthik Raju; Lynn A Spruce; Steven H Seeholzer; Harry Ischiropoulos
Journal:  J Proteomics       Date:  2013-06-05       Impact factor: 4.044

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.